BfArM lists urgent EPflex guidewire notice, but the defect sits in the manufacturer's advisory

What happened

On 9 November 2026, BfArM listed an urgent field safety notice (FSN) from EPflex Feinwerktechnik GmbH covering "various guidewires". The listing points readers to the manufacturer's advisory notice for the details.

That is all the public record shows so far. The records do not say which guidewire models or lots are affected, what the problem is, how many devices are involved, or what users are asked to do. They also do not say whether the action is a recall, a return, an inspection, a software or labelling change, or a precautionary communication. Any claim about the nature or severity of the issue would be speculation.

Why a thin listing still matters

An FSN is the manufacturer's formal communication to users about a field safety corrective action. It is the main route by which hospitals and distributors learn that a device already on the market needs attention. Regulators generally publish these notices, or links to them, so the information reaches the whole supply chain. The label "urgent" is the manufacturer's own framing and signals that action is expected without delay.

The BfArM listing works as a pointer rather than a summary. The operative content, including affected product identifiers, the risk description and the required user actions, is in the PDF attached to the entry. Compliance teams that rely on regulator headlines alone will miss the information they need to act.

One day, several device and quality signals

The EPflex notice was not the only device-related item to surface on 9 November. BfArM also listed an urgent FSN from Tontarra Medizintechnik for a 24Fr rotatable Quick-Lock inner sheath with a yellow ceramic tip, an endoscope accessory. It listed a Beckman Coulter notice for COULTER DxH Diluent, a haematology reagent. In both cases the defect and the user actions are only in the manufacturer's attached advisory. In the Netherlands, IGJ reported Baxter's voluntary correction of certain TruSystem 7000 and 7500 surgical tables after customers reported the main lift dropping to its lowest position during use.

Greece's EOF separately ordered the recall of every non-expired lot of the medical device Steriflush Syringes NaCl 0.9%, with the lots listed in a table attached to its decision. Outside devices, Health Canada reported a Type II national recall of Pendopharm's 25 mg and 50 mg diphenhydramine capsules after N-Nitroso-N-Desmethyl Diphenhydramine exceeded specification in seven lots.

These items involve different manufacturers, products and regulators, and the records give no common cause. A single day's postings should not be read as a trend. They do illustrate how varied the quality and vigilance signals are that a compliance function has to triage: guidewires, reagents, surgical tables, flush syringes and an impurity-driven drug recall.

Who is affected and what to check

The first group is hospitals, cath labs and clinics that stock EPflex guidewires. They need to establish whether any affected products are in inventory, in procedure packs or on consignment. The second is distributors and kit assemblers, who may have forwarded the devices as components. The third is manufacturers that integrate third-party guidewires into their own products, where the notice may trigger an assessment of their own vigilance obligations. The records do not say whether the EPflex action extends beyond Germany, so teams in other EU markets should not assume they are outside its scope.

Practically, the work is the same as for any FSN. Retrieve the manufacturer's notice, match product codes and lots against stock and traceability data, quarantine what is affected if the notice requires it, and document the response. Most FSNs also ask users to return an acknowledgement form to the manufacturer, which creates a record to keep for audit.

What to watch

The key unknowns are the substance of the EPflex advisory and whether other national authorities publish it. Watch for any follow-up from BfArM or EPflex, such as a revised notice, an extension of the affected range or closure information. Also note that the Dutch inspectorate posted an inspection report on Byondis B.V. after a September 2026 visit, but the listing does not give findings. That is a reminder that regulator postings often lag the underlying detail, and the primary document is what counts.